Pharmaceutical Technology

MAY 18, 2023

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. Pivotal trials on LMN-201 are expected to commence in 2023. It is compatible with standard-of-care antibiotics.

Bacterium 130

Bacterium Bacteria FDA Approval Trials 130

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccine Vaccination 75

XTalks

NOVEMBER 10, 2020

Update (November 11, 2020): Quebec-based biopharmaceutical company Medicago has announced positive results from a Phase I trial of its candidate plant-derived vaccine. Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52

The Pharma Data

MARCH 21, 2022

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. The anti-cancer molecule salinosporamide A, also called Marizomb, is in Phase III clinical trials to treat glioblastoma, a brain cancer. That was surprising,” she said. The molecule has a small but complex ring structure.

Bacterium 52

Bacterium Scientist Clinical Trials Clinical Trials 52

XTalks

JULY 25, 2023

Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Moreover, the clinical trials demonstrated that Cyfendus exhibited a favorable tolerability profile. What Is Anthrax? Additionally, at Day 64, 86.6

FDA Approval 98

FDA Approval Vaccine Vaccination Antibody 98

XTalks

JANUARY 20, 2021

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments).

Immune Response 52

Immune Response Research Allergies Protein 52